In case of ALK-positive NSCLC, iruplinalkib, a new generation ALK-inhibitor showed in the phase 2 INTELLECT trial (NCT04641754) significant antitumoral activity without high-grade toxicities, even in crizotinib-resistant patients.790. Here, ALK is linked to non-small cell lung carcinoma.